MWG Caph Ltd Makes New Investment in Lyell Immunopharma, Inc. $LYEL

MWG Caph Ltd acquired a new position in shares of Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 1,008,116 shares of the company’s stock, valued at approximately $31,030,000. Lyell Immunopharma accounts for 42.9% of MWG Caph Ltd’s investment portfolio, making the stock its 2nd biggest holding.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. AQR Capital Management LLC boosted its position in Lyell Immunopharma by 773.5% during the first quarter. AQR Capital Management LLC now owns 174,279 shares of the company’s stock worth $94,000 after purchasing an additional 154,327 shares during the period. Marshall Wace LLP acquired a new stake in shares of Lyell Immunopharma during the second quarter worth $94,000. Bridgeway Capital Management LLC acquired a new stake in shares of Lyell Immunopharma during the second quarter worth $159,000. BBR Partners LLC acquired a new stake in shares of Lyell Immunopharma during the fourth quarter worth $210,000. Finally, Walleye Capital LLC acquired a new stake in shares of Lyell Immunopharma during the second quarter worth $258,000. 66.05% of the stock is owned by institutional investors.

Lyell Immunopharma Trading Up 0.6%

Shares of NASDAQ LYEL opened at $12.52 on Thursday. The company has a market cap of $292.14 million, a price-to-earnings ratio of -0.91 and a beta of -0.09. Lyell Immunopharma, Inc. has a 12 month low of $8.46 and a 12 month high of $45.00. The stock has a 50-day moving average price of $18.66 and a two-hundred day moving average price of $23.03.

Lyell Immunopharma (NASDAQ:LYEL) last issued its earnings results on Wednesday, May 6th. The company reported ($1.10) EPS for the quarter, hitting the consensus estimate of ($1.10). The firm had revenue of $0.00 million during the quarter, compared to the consensus estimate of $0.00 million. Lyell Immunopharma had a negative return on equity of 85.71% and a negative net margin of 794,858.12%. On average, sell-side analysts predict that Lyell Immunopharma, Inc. will post -7.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on LYEL shares. Zacks Research raised Lyell Immunopharma from a “strong sell” rating to a “hold” rating in a report on Monday, May 18th. Citigroup reissued a “market outperform” rating on shares of Lyell Immunopharma in a report on Tuesday, June 9th. Citizens Jmp reissued a “market outperform” rating and set a $34.00 target price on shares of Lyell Immunopharma in a report on Monday. Weiss Ratings reissued a “sell (d-)” rating on shares of Lyell Immunopharma in a report on Tuesday, April 21st. Finally, HC Wainwright reissued a “buy” rating and set a $45.00 target price on shares of Lyell Immunopharma in a report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $43.00.

Lyell Immunopharma Profile

Lyell Immunopharma is a clinical-stage biotechnology company focused on developing next-generation T cell therapies for cancer. Leveraging a proprietary platform that combines cell therapy, gene editing and molecular discovery, Lyell seeks to overcome key barriers in the treatment of solid tumors. The company’s approach centers on engineering T cells to enhance their persistence, functionality and resistance to the immunosuppressive tumor microenvironment.

The company’s pipeline includes multiple autologous T cell programs engineered to target tumor-associated antigens in solid malignancies such as melanoma, ovarian and pancreatic cancers.